Physician profile
Dilini Daswatta
NPI 1982992293
$1,090.76
in general payments reported to CMS, 2019-2025
15 companies · $6.64 in 2025
The $6.64 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $238 · 2021: $325 · 2023: $3.08 · 2024: $46.84 · 2025: $6.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $56.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $56.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $212.58 | 2019-2021 | |
| Horizon Therapeutics Plc | $180.19 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $156.03 | 2019-2021 | |
| Akebia Therapeutics INC | $92.86 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $62.48 | 2021 | |
| Alexion Pharmaceuticals, INC. | $61.06 | 2019 | |
| Travere Therapeutics, INC. | $56.56 | 2023-2025 | Filspari |
| Daiichi Sankyo INC. | $53.63 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $52.84 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $51.32 | 2019 | |
| Opko Pharmaceuticals, LLC | $38.88 | 2019-2020 | |
| Amgen INC. | $23.18 | 2019 | |
| Shire North American Group INC | $21.33 | 2019 | |
| Glaxosmithkline, LLC. | $16.66 | 2021 | |
| Fresenius USA Marketing, INC. | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dilini Daswatta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.